Corline Biomedical AB - Asset Resilience Ratio

Latest as of December 2025: 20.85%

Corline Biomedical AB (CLBIO) has an Asset Resilience Ratio of 20.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Corline Biomedical AB's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Skr20.56 Million

≈ $2.21 Million USD Cash + Short-term Investments

Total Assets

Skr98.58 Million

≈ $10.61 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Corline Biomedical AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Corline Biomedical AB total assets.

Liquid Assets Composition Over Time

This chart breaks down Corline Biomedical AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Corline Biomedical AB (CLBIO) financial obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr20.56 Million	20.85%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr20.56 Million	20.85%

Asset Resilience Insights

Good Liquidity Position: Corline Biomedical AB maintains a healthy 20.85% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Corline Biomedical AB Industry Peers by Asset Resilience Ratio

Compare Corline Biomedical AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Corline Biomedical AB (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Corline Biomedical AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	20.85%	Skr20.56 Million ≈ $2.21 Million	Skr98.58 Million ≈ $10.61 Million	+2.21pp
2024-12-31	18.64%	Skr17.67 Million ≈ $1.90 Million	Skr94.76 Million ≈ $10.20 Million	+1.65pp
2023-12-31	16.99%	Skr17.01 Million ≈ $1.83 Million	Skr100.11 Million ≈ $10.77 Million	-8.76pp
2022-12-31	25.75%	Skr26.21 Million ≈ $2.82 Million	Skr101.78 Million ≈ $10.95 Million	-15.20pp
2021-12-31	40.95%	Skr41.63 Million ≈ $4.48 Million	Skr101.66 Million ≈ $10.94 Million	+26.09pp
2020-12-31	14.86%	Skr8.66 Million ≈ $932.28K	Skr58.28 Million ≈ $6.27 Million	-20.99pp
2019-12-31	35.85%	Skr22.86 Million ≈ $2.46 Million	Skr63.75 Million ≈ $6.86 Million	-8.09pp
2018-12-31	43.94%	Skr27.64 Million ≈ $2.97 Million	Skr62.91 Million ≈ $6.77 Million	+11.16pp
2017-12-31	32.78%	Skr16.86 Million ≈ $1.81 Million	Skr51.43 Million ≈ $5.53 Million	+4.03pp
2016-12-31	28.74%	Skr11.86 Million ≈ $1.28 Million	Skr41.27 Million ≈ $4.44 Million	--

pp = percentage points

About Corline Biomedical AB

ST:CLBIO Sweden Biotechnology

Market Cap

$39.94 Million

Skr371.09 Million SEK

Market Cap Rank

#22830 Global

#428 in Sweden

Share Price

Skr14.20

Change (1 day)

-3.73%

52-Week Range

Skr14.20 - Skr21.20

All Time High

Skr28.20